The Role of Gene Expression Profiling in the Management of Cutaneous Squamous Cell Cancer: A Review
Open Access
Abstract
Cutaneous squamous cell carcinoma (cSCC) is the second most common form of skin cancer, with an increasing global incidence. While most cases are successfully treated with surgical excision, a subset can metastasize, leading to significant morbidity and mortality. Current staging systems based on clinical and histopathological features have shown limitations in accurately predicting metastatic risk. This review examines the role of gene expression profiling (GEP), particularly the 40-gene expression profile (40-GEP) test, in improving risk stratification and management of cSCC. We assess the prognostic value of the 40-GEP test, its integration with current staging systems, and its impact on clinical decision-making. Recent studies suggest that incorporating GEP results with traditional staging methods can enhance the identification of high-risk patients, potentially leading to more personalized treatment strategies. The review also explores the challenges of implementing GEP in routine clinical practice, including cost-effectiveness considerations and the need for standardization. Finally, we discuss the implications for future cSCC management and highlight areas for further research. As molecular profiling techniques continue to evolve, GEP represents a promising approach to optimizing care for cSCC patients, aligning with the growing emphasis on personalized medicine in oncology.Keywords
All Related Versions
This publication has 72 references indexed in Scilit:
- Prevalence of Immunosuppression Among US AdultsJAMA, 2024
- Prognostic Gene Expression Profiling in Cutaneous MelanomaJAMA Dermatology, 2020
- Performance of the American Joint Committee on Cancer Staging Manual, 8th Edition vs the Brigham and Women’s Hospital Tumor Classification System for Cutaneous Squamous Cell CarcinomaJAMA Dermatology, 2019
- Nationwide Incidence of Metastatic Cutaneous Squamous Cell Carcinoma in EnglandJAMA Dermatology, 2019
- Prevalence of Immunosuppression Among US Adults, 2013JAMA, 2016
- Increased Risk of Cutaneous Squamous Cell Carcinoma After Vismodegib Therapy for Basal Cell CarcinomaJAMA Dermatology, 2016
- Evaluation of 122 advanced‐stage cutaneous squamous cell carcinomas by comprehensive genomic profiling opens the door for new routes to targeted therapiesCancer, 2015
- Incidence Estimate of Nonmelanoma Skin Cancer (Keratinocyte Carcinomas) in the US Population, 2012JAMA Dermatology, 2015
- Evaluation of AJCC Tumor Staging for Cutaneous Squamous Cell Carcinoma and a Proposed Alternative Tumor Staging SystemJAMA Dermatology, 2013
- Incidence Estimate of Nonmelanoma Skin Cancer in the United States, 2006Archives of Dermatology, 2010